Gilead Sciences

News

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

News

Gilead’s CD47 woes continue, this time in solid tumours

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug

News

Study backs safety of Gilead CAR-T as outpatient therapy

CAR-T therapies can achieve remarkable efficacy in the treatment of haematological cancers, but the risk of side effects means that the cell infusions are almost always ad

News

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),

Gilead’s Trodelvy woes rise with failed bladder cancer trial

FDA clears BMS’ Breyanzi for follicular lymphoma

Gilead and MSD say weekly oral therapy controls HIV

Gilead’s CD47 woes continue, this time in solid tumours

Study backs safety of Gilead CAR-T as outpatient therapy

Gilead to buy liver disease specialist CymaBay for $4.3bn

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks